IP Library › Granted Patent US 11,192,926

Granted Patent B2

US 11,192,926 · App. 16/500,331 · Granted Dec 7, 2021

Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use

Inventors: Neil P. King (Seattle, WA); David Baker (Seattle, WA); Brooke Nickerson (Seattle, WA); Lance Joseph Stewart (Seattle, WA); Laurent Perez (Bellinzona, CH); Antonio Lanzavecchia (Bellinzona, CH); Jessica Marcandalli (Bellinzona, CH)

Assignees: University of Washington; Institute for Research in Biomedicine

C07K14/005 A61K39/12 A61P31/14 B82Y5/00 C12N7/00 A61K2039/575 C07K2319/735 C12N2760/18022 C12N2760/18322 C12N2760/18522

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,192,926
App. No.: 16/500,331
Granted: Dec 7, 2021
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructures; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

Claims (116)

1. A method for generating an immune response to paramyxovirus and/or pneumovirus F protein in a subject, comprising administering to the subject in need thereof an effective amount of a nanostructure to generate the immune response, wherein the nanostructure, comprises:

(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;

(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;

wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and

wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, on an exterior of the nanostructure; wherein:

(I) (a) the first polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 1 00% identity to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-51; and

(b) the second polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-51; and/or

(II) the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of selected from the group consisting of SEQ ID NOS:53, 61-68, and 101 without the signal peptide of MELLILKANAITTILTAVTFCFASG (SEQ ID NO: 59).

2. The method of claim 1 , wherein:

(a) the first polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-51; and

3. The method of claim 1 , wherein the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its full length to a polypeptide to the amino acid sequence selected from the group consisting of SEQ ID NOS:53, 61-68, and 101 without the signal peptide of MELLILKANAITTILTAVTFCFASG (SEQ ID NO: 59).

4. The method of claim 1 , wherein the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of an RSV F protein or mutant thereof selected from the group consisting of SEQ ID NO:53 and 61-64, wherein the polypeptide includes one or more of the following residues: 671, 149C, 458C, 46G, 465Q, 215P, 92D, and 487Q.

5. The method of claim 1 , wherein the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of an MPV F protein or mutant thereof selected from the group consisting of SEQ ID NO:65-68 and 101 without the signal peptide of MELLILKANAITTILTAVTFCFASG (SEQ ID NO: 59), wherein the polypeptide includes one or more of the following residues: 113C, 120C, 339C, 160F, 177L, 185P, and 426C.

6. The method of claim 1 , wherein the first polypeptides and the second polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequences selected from the following pairs:

SEQ ID NO:1 and SEQ ID NO-2 (I53-34A and I53-34B);

SEQ ID NO:3 and SEQ ID NO-4 (I53-40A and 153-40B);

SEQ ID NO:3 and SEQ ID NO:24 (I53-40A and 153-40B.1);

SEQ ID NO:23 and SEQ ID NO:4 (153-40A.1 and 153-40B);

SEQ ID NO:35 and SEQ ID NO:36 (I53-40A genus and I53-40B genus);

SEQ ID NO:5 and SEQ ID NO-6 (I53-47A and 153-47B);

SEQ ID NO:5 and SEQ ID NO:27 (I53-47A and 153-47B.1);

SEQ ID NO:5 and SEQ ID NO:28 (I53-47A and I53-47B.1NegT2);

SEQ ID NO:25 and SEQ ID NO:6 (I53-47A.1 and 153-47B);

SEQ ID NO:25 and SEQ ID NO:27 (I53-47A.1 and I53-47B.1);

SEQ ID NO:25 and SEQ ID NO:28 (I53-47A.1 and I53-47B.1NegT2);

SEQ ID NO:26 and SEQ ID NO:6 (I53-47A.1NegT2 and I53-47B);

SEQ ID NO:26 and SEQ ID NO:27 (I53-47A.1NegT2 and I53-47B.1);

SEQ ID NO:26 and SEQ ID NO:28 (I53-47A.1NegT2 and 153-47B.1 NegT2);

SEQ ID NO:37 and SEQ ID NO:38 (I53-47A genus and I53-47B genus);

SEQ ID NO:7 and SEQ ID NO:8 (I53-50A and I53-50B);

SEQ ID NO:7 and SEQ ID NO:32 (153-50A and I53-50B.1);

SEQ ID NO:7 and SEQ ID NO:33 (I53-50A and I53-50B.1NegT2);

SEQ ID NO:7 and SEQ ID NO:34 (I53-50A and I53-50B.4PosT 1);

SEQ ID NO:29 and SEQ ID NO:8 (I53-50A.1 and I53-50B);

SEQ ID NO:29 and SEQ ID NO:32 (I53-50A.1 and I53-50B.1);

SEQ ID NO:29 and SEQ ID NO:33 (I53-50A.1 and I53-50B.1NegT2);

SEQ ID NO:29 and SEQ ID NO:34 (I53-50A.1 and I53-50B.4PosT 1);

SEQ ID NO:30 and SEQ ID NO:8 (I53-50A.1 NegT2 and I53-50B);

SEQ ID NO:30 and SEQ ID NO:32 (I53-50A.1NegT2 and I53-50B.1);

SEQ ID NO:30 and SEQ ID NO:33 (I53-50A.1NegT2 and I53-50B.1NegT2);

SEQ ID NO:30 and SEQ ID NO:34 (I53-50A.1NegT2 and I53-50B.4PosT 1);

SEQ ID NO:31 and SEQ ID NO:8 (I53-50A.1PosT1 and I53-50B);

SEQ ID NO:31 and SEQ ID NO:32 (I53-50A.1PosT1 and I53-50B.1);

SEQ ID NO:31 and SEQ ID NO:33 (I53-50A.1PosT1 and I53-50B.1NegT2);

SEQ ID NO:31 and SEQ ID NO:34 (I53-50A.1PosT1 and I53-50B.4PosT1);

SEQ ID NO:39 and SEQ ID NO:40 (I53-50A genus and I53-50B genus);

SEQ ID NO:9 and SEQ ID NO:10 (I53-51A and I53-51B);

SEQ ID NO:11 and SEQ ID NO:12 (I52-03A and I52-03B);

SEQ ID NO:13 and SEQ ID NO:14 (I52-32A and I52-32B);

SEQ ID NO:15 and SEQ ID NO:16 (152-33A and I52-33B);

SEQ ID NO:17 and SEQ ID NO:18 (132-06A and I32-06B);

SEQ ID NO:19 and SEQ ID NO:20 (132-19A and I32-19B);

SEQ ID NO:21 and SEQ ID NO:22 (132-28A and I32-28B);

SEQ ID NO:23 and SEQ ID NO:24 (I53-40A.1 and I53-40B.1);

SEQ ID NO:41 and SEQ ID NO:42 (T32-28A and T32-28B);

SEQ ID NO:43 and SEQ ID NO:44 (T33-09A and T33-09B);

SEQ ID NO:45 and SEQ ID NO:46 (T33-15A and T33-15B);

SEQ ID NO:47 and SEQ ID NO:48 (T33-21A and T33-21B);

SEQ ID NO:49 and SEQ ID NO:50 (T33-28A and T32-28B); and

SEQ ID NO:51 and SEQ ID NO:44 (T33-31B and T33-09B).

7. The method of claim 1 , wherein the first polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of I53-50A (SEQ ID NO:7), I53-50A.1 (SEQ ID NO:29), I53-50A.1NegT2 (SEQ ID NO:30), and I53-50A.1PosT1 (SEQ ID NO:31), and the second polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of I53-50B (SEQ ID NO:8), I53-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), and I53-50B.4PosT1 (SEQ ID NO:34).

8. The method of claim 1 , wherein the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, are expressed as a fusion protein with the first polypeptides.

9. The method of claim 1 , wherein the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of DS-Cav1 (SEQ ID NO:53).

10. The method of claim 8 , wherein each fusion protein comprises an amino acid linker positioned between the first polypeptide and the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragment thereof.

11. The method of claim 10 , wherein the amino acid linker sequence comprises one or more trimerization domain.

12. The method of claim 10 , wherein the amino acid linker sequence comprises the amino acid sequence GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO:54).

13. The method of claim 10 , wherein the amino acid linker sequence comprises a Gly-Ser linker.

14. The method of claim 8 , wherein the fusion protein comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of SEQ ID NOS:69-100.

15. The method of claim 14 , wherein:

(a) when each fusion protein is DS-Cav1-foldon-T33-31A (SEQ ID NO:69) or DS-Cav1-T33-31A (SEQ ID NO:70), and each second polypeptide is T33-31B (SEQ ID NO:44);

(b) when each fusion protein is DS-Cav1-foldon-T33-15B (SEQ ID NO:71) or DS-Cav1-T33-15B (SEQ ID NO:72), and each second polypeptide is T33-15A (SEQ ID NO:45);

(c) when each fusion protein is DS-Cav1-foldon-I53-50A (SEQ ID NO:73) or DS-Cav1-I53-50A (SEQ ID NO:74), and each second polypeptide is I53-50B (SEQ ID NO:8), I53-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), or I53-50B.4PosT1 (SEQ ID NO:34); or

(d) when each fusion protein is DS-Cav1-I32-28A (SEQ ID NO:75), and each second polypeptide is I32-28B (SEQ ID NO:22).

16. The method of claim 9 , wherein each first polypeptide comprises a fusion protein of DS-Cav1 (SEQ ID NO:53) linked to SEQ ID NO:7 (I53-50A) via an amino acid linker.

17. The method of claim 16 , wherein each second polypeptide comprises the amino acid sequence selected from the group consisting of I53-50B (SEQ ID NO:8), I53-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), or I53-50B.4PosT1 (SEQ ID NO:34).

18. The method of claim 16 , wherein each second polypeptide comprises the amino acid sequence of I53-50B.4PosT1 (SEQ ID NO:34).

19. The method of claim 1 , wherein the nanostructure:

(a) binds prefusion F-specific antibodies including but not limited to monoclonal antibody 25 ;

(b) forms a symmetrical structure, including but not limited to an icosahedral structure;

(d) is stable in 2.25 M guanidine hydrochloride.

20. A method for treating or limiting a paramyxovirus and/or pneumovirus infection in a subject, comprising administering to the subject in need thereof an effective amount of a nanostructure, thereby treating or preventing paramyxovirus and/or pneumovirus infection in the subject, wherein the nanostructure, comprises:

(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;

(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;

wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and

wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, on an exterior of the nanostructure; wherein:

(I) (a) the first polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-51; and

21. The method of claim 1 , wherein the administering results in production of paramyxovirus and/or pneumovirus neutralizing antibodies in the subject.

22. The method of claim 21 , wherein the neutralizing antibodies are present in sera of the subject at a titer ( 1 /ID 50 ) of at least 9,400.

23. A process for assembling a nanostructure in vitro, wherein the nanostructure, comprises:

(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;

(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;

wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and

wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof, on an exterior of the nanostructure, comprising mixing two or more nanostructure components in aqueous conditions to drive spontaneous assembly of the nanostructure; wherein:

(I) (a) the first polypeptides comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-51; and

24. The method of claim 1 , wherein:

(I) the first polypeptides comprise an amino acid sequence having at least 95% identity to SEQ ID NO: 7 (I53-50A) without the N-terminal methionine of residue 1 ; and

(b) the second polypeptides comprise an amino acid sequence having at least 95% identity to SEQ ID NO: 8 (I53-50B).

25. The method of claim 24 , wherein:

(II) the one or more paramyxovirus and/or pneumovirus F proteins, or antigenic fragments thereof are RSV F proteins or mutants thereof having an amino acid sequence at least 95% identity to SEQ ID NO: 53 (Ds-Cav1) without the signal peptide of MELLILKANAITTILTAVTFCFASG (SEQ ID NO: 59).

26. The method of claim 25 , wherein the RSV F proteins or mutants thereof are RSV F mutants having an amino acid sequence identical to SEQ ID NO: 53 (Ds-Cav1) without the signal peptide of MELLILKANAITTILTAVTFCFASG (SEQ ID NO: 59).

27. The method of claim 25 , wherein the first polypeptides are fusion proteins comprising, in N to C-terminal order, an RSV F protein or mutant thereof having an amino acid sequence at least 95% identity to SEQ ID NO: 53 (Ds-Cav1) without the signal peptide of MELLILKANAITTILTAVTFCFASG (SEQ ID NO: 59), and a polypeptide having at least 95% identity to SEQ ID NO: 7 (I53-50A) without the N-terminal methionine of residue 1 .

28. The method of claim 25 , wherein the first polypeptides are fusion proteins comprising, in N to C-terminal order:

an RSV F protein mutant having an amino acid sequence identical to SEQ ID NO: 53 (Ds-Cav1) without the signal peptide of MELLILKANAITTILTAVTFCFASG (SEQ ID NO: 59), and

a polypeptide having an amino acid sequence identical to SEQ ID NO: 7 (I53-50A) without the N-terminal methionine of residue 1 .

29. The method of claim 25 , wherein the second polypeptides comprise an amino acid sequence at least 95% identical to a polypeptide selected from the group consisting of 153-50B (SEQ ID NO:8), 153-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), and I53-50B.4PosT1 (SEQ ID NO:34).

30. The method of claim 25 , wherein the second polypeptides comprise an amino acid sequence at least 94% identical to 153-50B (SEQ ID NO:8).

31. The method of claim 26 , wherein the RSV F proteins or mutants thereof are RSV F protein mutants that include the amino acid substitutions S155C, S290C, S190F, and V207L.

32. The method of claim 31 , wherein the method elicits protective responses against respiratory syncytial virus (RSV).

33. The method of claim 31 , wherein the method elicits improved protective responses against respiratory syncytial virus (RSV) in mice compared to postfusion RSV F.

34. The method of claim 31 , wherein the method elicits improved protective responses against respiratory syncytial virus (RSV) in macaques compared to postfusion RSV F.

Assignments (3)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020

From: HOWARD HUGHES MEDICAL INSTITUTE

To: UNIVERSITY OF WASHINGTON

Reel/Frame 053233/0699 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2019

From: PEREZ, LAURENT; LANZAVECCHIA, ANTONIO; MARCANDALLI, JESSICA

To: INSTITUTE FOR RESEARCH IN BIOMEDICINE

Reel/Frame 050614/0634 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2019

From: KING, NEIL P.; BAKER, DAVID; NICKERSON, BROOKE; STEWART, LANCE JOSEPH

To: UNIVERSITY OF WASHINGTON

Reel/Frame 050614/0687 →

Continuity (2)

Provisional Application 62481331 · Apr 4, 2017

Related Publication 20200392187A1 · Dec 17, 2020